Bincy Abraham, MD, on Positioning Biosimilars in the Management of IBD
09/26/2020
Bincy Abraham, MD, reviews her presentation on positioning biosimilars as first-line or switch therapies for patients with IBD, which she presented at the virtual Advances in Inflammatory Bowel Disease 2020 regional meeting on September 26.
Additional Resources:
For more information about AIBD 2020 and to register for the AIBD Annual Meeting in December, visit https://www.advancesinibd.com
Bincy Abraham, MD, is director of the Fondren Inflammatory Bowel Disease Program at Houston Methodist Hospital in Houston, Texas.
